+1-888-308-5802     
News Contact Us

Calithera begins clinical study of drug combination in cancer patients

Author : Saif Ali Bepari | Published Date : 2019-07-04 

Calithera Biosciences, a clinical-stage biotech company focused on developing small molecule drugs to treat cancer and life-threatening diseases, recently announced that it has treated the first patient in an open-label Phase 1/2 clinical trial of Glutaminase inhibitor telaglenastat combined with Pfizer’s CDK 4/6 inhibitor palbociclib, alternatively called Ibrance.

The study will be evaluating the anti-tumor activity and safety of telaglenastat-pluspalbociclib combination in patients with KRAS-mutated non-small cell lung cancer (NSCLC) and KRAS-mutated colorectal cancer (CRC).

President and chief executive officer at Calithera, Susan Molineaux said that preclinical data indicate palbociclib and telaglenastat perform synergistically in KRAS-mutated tumors, which will offer a different approach to the challenges that are associated with the treatment of KRAS-mutated cancers.

The company is looking forward to launching a second trial with Pfizer and expect that the combination of telaglenastat and palbociclib will fill a major treatment gap for both the medical professionals and patients, Molineaux  mentioned.

Apparently, telaglenastat is designed in a way that it is capable of blocking glutamine consumption in tumor cells. Telaglenastat reportedly showed synergistic antitumor effects in a preclinical KRAS-mutated cancer models. It was used with CDK4/6 inhibitors like palbociclib, that enhanced blocking of cancer cell proliferation and cell cycle arrest.

According to reliable sources, the Phase 1/2 clinical trial will be evaluating the anti-tumor activity and the safety of the combination of telaglenastat and palbociclib in patients suffering with locally advanced KRAS-mutated NSCLC or KRAS-mutated CRC, both of which are intolerant to standard therapies and refractory.

For the record, Calithera has initiated a second trial that is part of the Pfizer’s current clinical trial agreement. The first trial is reportedly testing the combination of telaglenastat with PARP inhibitor talazaporib. It is underway in patients with triple negative breast cancer ( TNBC), CRC and renal cell carcinoma (RCC). The first trial begun enrolling patients in March and Pfizer will provide talazoparib and palbociclib along with monetary support as per the agreement.

Source Credit- http://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-initiates-phase-12-trial-telaglenastat-0?field_nir_news_date_value%5bmin%5d=

About Author

Saif Ali Bepari

Saif Ali Bepari

A qualified Computer Science graduate, Saif Ali Bepari, armed with more of an inclination toward writing than coding, commenced his journey in the content industry as a freelancer. Currently penning down content for fractovia.org and a couple of other portals, Saif has also tinkered with creative writing, technical writing, blog writing, and copywriting. He can be contacted at- [email protected] | https://twitter.com/Saif_B17

Related News

Co-working firm Spacious the latest in WeWork’s acquisition spree

Published Date: 2019-08-29         Author: Saif Ali Bepari

New York-based co-working business, The We Company, formerly known as WeWork, has today announced its acquisition of rival start-up Spacious. The company, formed three years ago, is focused on converting restaurants closed during the day into efficient spaces for co-working. WeWork is a part of many... Read More

HAPSMobile wins federal approval to fly unmanned aircraft above Hawaii

Published Date: 2019-08-09         Author: Saif Ali Bepari

The development of HAWK30 focuses on providing an enhanced stratospheric telecommunication platform Japan based HAPSMobile- a subsidiary of SoftBank Corp., has reportedly confirmed that it has received an Authorizing Certificate from US Federal Aviation Administration to fly HAWK 30, a solar oper... Read More

FEMSA to ink joint venture deal with Raizen Conveniencias in Brazil

Published Date: 2019-08-07         Author: Saif Ali Bepari

Mexico based Fomento Economico Mexicano (FEMSA), a leading retail and beverage company, has reportedly announced that it will sign an agreement with Raizen to enter into a 50-50 joint venture. The collaboration aims at creating a powerful platform for FEMSA in the convenience store market in Brazil ... Read More

© 2019 Fractovia. All Rights Reserved